176 related articles for article (PubMed ID: 25644622)
1. Prognostic relevance of acquired uniparental disomy in serous ovarian cancer.
Tuna M; Ju Z; Smid M; Amos CI; Mills GB
Mol Cancer; 2015 Feb; 14(1):29. PubMed ID: 25644622
[TBL] [Abstract][Full Text] [Related]
2. Genome-Wide Profiling of Acquired Uniparental Disomy Reveals Prognostic Factors in Head and Neck Squamous Cell Carcinoma.
Tuna M; Liu W; Amos CI; Mills GB
Neoplasia; 2019 Nov; 21(11):1102-1109. PubMed ID: 31734631
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of acquired uniparental disomy (aUPD) in primary breast cancer.
Tuna M; Smid M; Martens JW; Foekens JA
Breast Cancer Res Treat; 2012 Feb; 132(1):189-96. PubMed ID: 21604015
[TBL] [Abstract][Full Text] [Related]
4. Genome-Wide Analysis of Head and Neck Squamous Cell Carcinomas Reveals HPV, TP53, Smoking and Alcohol-Related Allele-Based Acquired Uniparental Disomy Genomic Alterations.
Tuna M; Amos CI; Mills GB
Neoplasia; 2019 Feb; 21(2):197-205. PubMed ID: 30616092
[TBL] [Abstract][Full Text] [Related]
5. Common and distinct patterns of acquired uniparental disomy and homozygous deletions between lung squamous cell carcinomas and lung adenocarcinoma.
Tuna M; Mills GB; Amos CI
Neoplasia; 2023 Nov; 45():100932. PubMed ID: 37801862
[TBL] [Abstract][Full Text] [Related]
6. Association between acquired uniparental disomy and homozygous mutations and HER2/ER/PR status in breast cancer.
Tuna M; Smid M; Zhu D; Martens JW; Amos CI
PLoS One; 2010 Nov; 5(11):e15094. PubMed ID: 21152100
[TBL] [Abstract][Full Text] [Related]
7. The genomic landscape of TP53 and p53 annotated high grade ovarian serous carcinomas from a defined founder population associated with patient outcome.
Wojnarowicz PM; Oros KK; Quinn MC; Arcand SL; Gambaro K; Madore J; Birch AH; de Ladurantaye M; Rahimi K; Provencher DM; Mes-Masson AM; Greenwood CM; Tonin PN
PLoS One; 2012; 7(9):e45484. PubMed ID: 23029043
[TBL] [Abstract][Full Text] [Related]
8. Quantitative analysis of somatically acquired and constitutive uniparental disomy in gastrointestinal cancers.
Torabi K; Erola P; Alvarez-Mora MI; Díaz-Gay M; Ferrer Q; Castells A; Castellví-Bel S; Milà M; Lozano JJ; Miró R; Ried T; Ponsa I; Camps J
Int J Cancer; 2019 Feb; 144(3):513-524. PubMed ID: 30350313
[TBL] [Abstract][Full Text] [Related]
9. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
[TBL] [Abstract][Full Text] [Related]
10. Acquired uniparental disomy of chromosome 9p in hematologic malignancies.
Wang L; Wheeler DA; Prchal JT
Exp Hematol; 2016 Aug; 44(8):644-52. PubMed ID: 26646991
[TBL] [Abstract][Full Text] [Related]
11. Acquired Uniparental Disomy Regions Are Associated with Disease Outcome in Patients with Oral Cavity and Oropharynx But Not Larynx Cancers.
Tuna M; I Amos C; B Mills G
Transl Oncol; 2020 May; 13(5):100763. PubMed ID: 32305020
[TBL] [Abstract][Full Text] [Related]
12. Promoter CpG island methylation of genes in key cancer pathways associates with clinical outcome in high-grade serous ovarian cancer.
Dai W; Zeller C; Masrour N; Siddiqui N; Paul J; Brown R
Clin Cancer Res; 2013 Oct; 19(20):5788-5797. PubMed ID: 23965899
[TBL] [Abstract][Full Text] [Related]
13. Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation.
O'Shea D; O'Riain C; Gupta M; Waters R; Yang Y; Wrench D; Gribben J; Rosenwald A; Ott G; Rimsza LM; Holte H; Cazier JB; Johnson NA; Campo E; Chan WC; Gascoyne RD; Young BD; Staudt LM; Lister TA; Fitzgibbon J
Blood; 2009 Mar; 113(10):2298-301. PubMed ID: 19141865
[TBL] [Abstract][Full Text] [Related]
14. Loss-of-heterozygosity on chromosome 19q in early-stage serous ovarian cancer is associated with recurrent disease.
Skirnisdottir I; Mayrhofer M; Rydåker M; Akerud H; Isaksson A
BMC Cancer; 2012 Sep; 12():407. PubMed ID: 22967087
[TBL] [Abstract][Full Text] [Related]
15. Novel regions of acquired uniparental disomy discovered in acute myeloid leukemia.
Gupta M; Raghavan M; Gale RE; Chelala C; Allen C; Molloy G; Chaplin T; Linch DC; Cazier JB; Young BD
Genes Chromosomes Cancer; 2008 Sep; 47(9):729-39. PubMed ID: 18506749
[TBL] [Abstract][Full Text] [Related]
16. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
17. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.
Emmanuel C; Chiew YE; George J; Etemadmoghadam D; Anglesio MS; Sharma R; Russell P; Kennedy C; Fereday S; Hung J; Galletta L; Hogg R; Wain GV; Brand A; Balleine R; MacConaill L; Palescandolo E; Hunter SM; Campbell I; Dobrovic A; Wong SQ; Do H; Clarke CL; Harnett PR; Bowtell DD; deFazio A;
Clin Cancer Res; 2014 Dec; 20(24):6618-30. PubMed ID: 25316818
[TBL] [Abstract][Full Text] [Related]
18. Poor survival with wild-type TP53 ovarian cancer?
Wong KK; Izaguirre DI; Kwan SY; King ER; Deavers MT; Sood AK; Mok SC; Gershenson DM
Gynecol Oncol; 2013 Sep; 130(3):565-9. PubMed ID: 23800698
[TBL] [Abstract][Full Text] [Related]
19. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
[TBL] [Abstract][Full Text] [Related]
20. Long Non-coding RNA
Yim GW; Kim HJ; Kim LK; Kim SW; Kim S; Nam EJ; Kim YT
Cancer Res Treat; 2017 Jul; 49(3):656-668. PubMed ID: 27737536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
